The purpose of the study is to test the use of a drug called bromocriptine for women who have a condition called Peripartum cardiomyopathy; or PPCM. PPCM means you have a weak heart after giving birth. The study will look at how the heart muscle improves in women taking bromocriptine compared to a group of women given a placebo or inactive pill. Bromocriptine is approved by the United States Food and Drug Administration (FDA) to treat irregular periods and other symptoms that result from having high blood levels of a substance called prolactin. It is not approved for use in usual care to treat PPCM.

The U.S. Food and Drug Administration (FDA) has approved the steroid dexamethasone for both oral consumption, and injections through the following routes: intravenous, intramuscular, intraarticular, soft tissue, and intralesional. Dexamethasone is commonly used in surgery, but its use is generally up to the discretion of the treating physician whether it is used in lumbar disc herniation surgeries or not as this is an off-label use of dexamethasone not currently approved by IRB Approval Date: Sep 04, 2024; Written Consent with HIPAA Authorization ID #737119; Amendment ID #430440 VERSION 16, 8/29/2024 3 of 13 the FDA. In this study we would like to learn more about which patient population benefits the most from utilization of this drug intra-operatively after lumbar disc herniation.